The APS adapter protein couples the insulin receptor to the phosphorylation of c-Cbl and facilitates ligand-stimulated ubiquitination of the insulin receptor  by Ahmed, Z et al.
The APS adapter protein couples the insulin receptor to the
phosphorylation of c-Cbl and facilitates ligand-stimulated ubiquitination
of the insulin receptor
Z. Ahmed, B.J. Smith, T.S. Pillay*
Molecular Endocrinology Group, Institute of Cell Signalling and School of Biomedical Sciences, University of Nottingham Medical School,
Queen’s Medical Centre, Nottingham NG7 2UH, UK
Received 6 March 2000; received in revised form 9 May 2000
Edited by Giulio Superti-Furga
Abstract The APS adapter protein is rapidly tyrosine-phos-
phorylated following insulin stimulation. In insulin-stimulated
3T3-L1 adipocytes, APS co-precipitated with phosphorylated
c-Cbl. In CHO.T-APS cells overexpressing the insulin receptor
and APS, APS co-precipitated with c-Cbl but not in CHO.T
cells which do not express APS. APS-mediated recruitment of
c-Cbl to the insulin receptor led to rapid ubiquitination of the
insulin receptor L-subunit in CHO.T-APS but not in parental
CHO.T cells. These results suggest that the function of APS is to
facilitate coupling of the insulin receptor to c-Cbl in order to
catalyse the ubiquitination of the receptor and initiation of
internalisation or degradation. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Tyrosine kinase receptor catalytic domains are activated
following the binding of cognate ligands to the extracellular
domains. The binding of insulin to the K-subunit of the re-
ceptor triggers autophosphorylation of the L-subunit of the
receptor on a conserved set of tyrosine residues (Tyr 1158,
1162 and 1163) in the activation loop of the kinase domain
[1,2]. This results in maximal activation of the receptor tyro-
sine kinase and subsequent tyrosine phosphorylation of a
number of intracellular substrates, including the insulin recep-
tor substrate (IRS) family (IRS1,2,3,4) and Shc. Phosphory-
lation of these proteins then facilitates the activation of the
phosphatidylinositol 3-kinase and Ras-mitogen-activated pro-
tein kinase pathways, respectively [3].
Although, it was previously thought that the insulin recep-
tor utilised intermediates such as IRS and Shc to signal, recent
evidence indicates that the insulin receptor, by virtue of auto-
phosphorylation in the activation loop, can recruit signalling
adapters directly. For example, the family of adapter proteins
that include the Grb10/14 family bind directly to the activa-
tion loop of the insulin receptor [4]. More recently, we and
others identi¢ed Src homology 2 (SH2)-B and an adapter
protein containing a PH and SH2 domain (APS) as insulin
receptor binding proteins [5^9]. The APS protein [10] is the
newest distinct member of this family of adapter proteins that
include SH2-B splice variants, K, L and Q [8] and the lympho-
cyte speci¢c adapter protein, Lnk [11,12]. These are charac-
terised by the presence of a PH domain, proline rich regions
and an SH2 domain. APS was ¢rst identi¢ed as a c-kit inter-
acting protein [10] but was subsequently found to also interact
with the insulin receptor activation loop and found to be a
substrate for insulin-stimulated tyrosine phosphorylation in
intact cells. The expression of APS is restricted in comparison
with SH2-B [7]. APS appears to be highly expressed in adipose
tissue, skeletal muscle and heart which are target tissues for
insulin [6,7]. Since the role of APS in insulin signalling is not
understood, we stably expressed myc-tagged APS in Chinese
hamster ovary (CHO) cells expressing the insulin receptor and
studied initial signalling events in these cells.
2. Materials and methods
2.1. Materials, bu¡ers and antibodies
9E10 Myc antibody was prepared from 9E10 hybridoma. Antiphos-
photyrosine antibody RC20 conjugated to horseradish peroxidase
(HRP) and anti-c-Cbl antibodies were purchased from Transduction
Labs (Lexington, KY, USA). Anti-ubiquitin antibody was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-insulin
receptor antibody 83-14 was previously obtained from Ken Siddle.
Antipeptide insulin receptor peptide antibody was obtained from
Dr. J. Olefsky (UC San Diego, CA, USA). The N-terminus of rat
APS (amino acids 117^465) [13] was subcloned into a pGEX and
expressed as a glutathione S-transferase fusion protein in DH5K bac-
teria. The expressed protein was puri¢ed by a⁄nity chromatography
on glutathione agarose and used to immunise rabbits as described [6].
The resulting sera (anti-APS 6113-40) were screened using cell lysates
derived from CHO.T-APS cells and used to probe anti-Cbl immuno-
precipitates.
2.2. Expression vectors and cell lines
CHO.T cells were previously obtained from Dr. Gus Gustafson.
Myc-tagged rat APS [13] was kindly provided by Dr. David Ginty
(Johns Hopkins University, Baltimore, MD, USA) and subcloned into
pIRES Hygro (Clontech) and transfected into CHO.T cells using
Superfect (Qiagen). Forty-eight hours after transfection, the cells
were selected in 800 Wg/ml hygromycin and clones were isolated by
limiting dilution and screened using anti-myc 9E10 monoclonal anti-
body. Clones were maintained in 400 Wg/ml hygromycin.
2.3. Lysate preparation, immunoprecipitation and Western blotting
CHO.T cells were cultured and lysates prepared as previously de-
scribed [6,9]. Proteins were immunoprecipitated using 5^10 Wg of anti-
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body. Antibodies were immunoprecipitated using antimouse agarose
(monoclonal) or protein A Sepharose. Immunoprecipitates were then
analysed by immunoblotting and visualisation using HRP-conjugated
secondary antibodies and luminol-based substrates (Supersignal,
Pierce Chemical Company, Rockford, IL, USA).
3. Results and discussion
3.1. Insulin stimulates tyrosine phosphorylation of c-Cbl in cells
transfected with APS
The stimulation of some cell types with platelet-derived
growth factor (PDGF), erythropoietin or insulin results in
the tyrosine phosphorylation of APS on tyrosine residue 618
[7,10,14,15]. This phosphorylated tyrosine has been shown to
interact with the variant SH2 domain of Cbl [15]. In 3T3-L1
adipocytes, insulin stimulates the phosphorylation of c-Cbl
[16]. This does not occur in other cell types, including CHO
cells expressing high levels of insulin receptor, suggesting that
an accessory protein is required to facilitate phosphorylation
of Cbl in 3T3-L1 adipocytes. We performed a similar experi-
ment in di¡erentiated 3T3-L1 adipocytes. Insulin-stimulated
c-Cbl phosphorylation was determined by anti-Cbl immuno-
precipitation and antiphosphotyrosine immunoblotting. In ad-
dition, anti-c-Cbl immunoprecipitates revealed the presence of
a phosphoprotein of Mr 90^95 kDa (Fig. 1). Probing the
membranes with anti-APS antibody showed that this phos-
phoprotein was detected with an anti-APS antibody (Fig. 1).
We next examined c-Cbl phosphorylation in CHO.T-APS
cells (Fig. 2). Both CHO.T cells and CHO.T-APS cells were
stimulated with insulin and c-Cbl was immunoprecipitated
and its tyrosine phosphorylation state was examined by anti-
phosphotyrosine immunoblotting. In CHO.T-APS cells, a ty-
rosine phosphoprotein corresponding to the mobility of APS
was observed in whole cell lysates indicating that APS was
being phosphorylated to a high stoichiometry in these cells. In
CHO.T-APS cells (Fig. 1) insulin-stimulated rapid and robust
tyrosine phosphorylation of c-Cbl but no phosphorylation of
c-Cbl was observed in CHO.T cells which do not express
endogenous APS. This indicated that APS is su⁄cient to fa-
cilitate c-Cbl phosphorylation in response to insulin. Interest-
ingly, as we have previously shown, CHO.T cells express en-
Fig. 1. Insulin-stimulated phosphorylation in 3T3-L1 adipocytes.
Di¡erentiated 3T3L1 adipocytes were serum-starved and then stimu-
lated with 100 ng/ml insulin for 5 min. The cells were lysed and c-
Cbl was immunoprecipitated using monoclonal anti-Cbl. a: Immu-
noprecipitates were analysed using anti-phosphotyrosine conjugated
to HRP (RC-20HRP). The blot shown in (a) was then stripped and
analysed using polyclonal anti-APS (b) and anti-c-Cbl (c). w.c.l.,
whole cell lysates; IP, immunoprecipitating antibody; Blot, immu-
noblotting antibody.
Fig. 2. Overexpression of APS allows insulin-stimulated c-Cbl tyro-
sine phosphorylation. CHO.T cells stably transfected with myc-
tagged APS (CHO.T-APS) were serum-starved and stimulated with
insulin for 5 min. c-Cbl was then immunoprecipitated from these
cells. The immunoprecipitates were analysed by antiphosphotyrosine
immunoblotting (a). b: The membrane shown in (a) was then
stripped and reprobed for c-Cbl using polyclonal anti-Cbl. A sample
of the whole cell lysate is shown alongside for comparison. w.c.l.,
whole cell lysate; IP, immunoprecipitating antibody.
Fig. 3. APS-mediated interaction of c-Cbl with the insulin receptor.
The phosphorylation of c-Cbl was compared in CHO.T cells and
CHO.T cells stably transfected with pIRES Hygro APS (CHO.T-
APS). Cells were serum-starved overnight and stimulated with 100
ng/ml insulin for 5 min and solubilised. Cell lysates (200 mg) were
used for immunoprecipitation with monoclonal anti-Cbl antibody or
puri¢ed mouse IgG as a control. Proteins were separated by sodium
dodecyl sulphate^polyacrylamide gel electrophoresis and blotted
with (a) anti-phosphotyrosine antibody RC20H, (b) anti-myc 9E10
and (c) anti-IR peptide polyclonal antibody. IP, immunoprecipitat-
ing antibody; Blot, immunoblotting antibody.
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dogenous SH2-B [6] which is weakly phosphorylated by insu-
lin but does not appear to be su⁄cient to facilitate insulin-
stimulated phosphorylation of c-Cbl. In addition, in the c-Cbl
immunoprecipitates, we observed a phosphoprotein that was
similar in mobility to APS or the insulin receptor L-subunit
suggesting that one of these proteins was possibly present in
the c-Cbl immunoprecipitates (Fig. 2).
3.2. Co-precipitation of c-Cbl, insulin receptor and APS
We next determined whether insulin receptor could be de-
tected in the c-Cbl immunoprecipitates (Fig. 3). The immuno-
precipitates were also analysed by antiphosphotyrosine, anti-
insulin receptor and anti-myc immunoblotting (Fig. 3). Again,
in c-Cbl immunoprecipitates, we observed the co-precipitation
of a major phosphoprotein with c-Cbl as well as a weaker
phosphoprotein migrating between the position of c-Cbl and
APS. The membranes were then stripped and reprobed for
insulin receptor and APS. Insulin receptor is clearly detectable
in c-Cbl immunoprecipitates from insulin-stimulated CHO.T
APS cells (Fig. 3c). Similarly, using anti-myc 9E10 to detect
the presence of epitope-tagged APS, reveals that APS is
present in the c-Cbl immunoprecipitates from insulin-stimu-
lated CHO.T APS cells (Fig. 3b). Thus, these results indicate
that insulin stimulates the formation of a complex comprised
of the insulin receptor, c-Cbl and APS.
3.3. Insulin stimulates ubiquitination of the insulin receptor in
cells transfected with APS
c-Cbl has been shown to promote the ubiquitination of ty-
rosine kinase receptors by functioning as a RING-type E2-
dependent ubiquitin protein ligase [17^25]. The association of
c-Cbl with tyrosine kinase receptors catalyses the ubiquitina-
tion of these receptors and targets them for degradation and
this is dependent on the variant SH2 domain and RING ¢n-
ger region of c-Cbl [17,23^25]. We next addressed the question
of whether expression of APS facilitated or enhanced ubiqui-
tination of the insulin receptor (Fig. 4). CHO.T cells and
CHO.T APS cells were stimulated with insulin and the insulin
receptor was immunoprecipitated with anti-insulin receptor
antibody 83-14. The immunoprecipitates were analysed using
anti-ubiquitin antibody. Anti-ubiquitin blotting reveals the
presence of two major bands corresponding to the precursor
and the mature L-subunit. In CHO.T cells, we could only
observe ubiquitination of the precursor form of the insulin
receptor indicating that a substantial amount of unprocessed
precursor is ubiquitinated and targeted for degradation and
this does not alter with ligand stimulation. In contrast, ex-
pression of APS resulted in increased ubiquitination of the
mature L-subunit following ligand stimulation (Fig. 4).
The proto-oncogene c-Cbl is a substrate for a number of
tyrosine kinase receptors, including epidermal growth factor,
PDGF and CSF-1 [22,26]. These receptors appear to associate
directly with c-Cbl through its variant SH2 domain resulting
in the phosphorylation of c-Cbl. The increased association of
c-Cbl with these receptors facilitates ubiquitination and tar-
gets the receptors for degradation. In comparison, insulin
stimulation cannot result in c-Cbl phosphorylation even in
cells overexpressing insulin receptor [16]. An exception to
this is the 3T3-L1 adipocyte which is widely used as a model
cell line for the study of insulin signalling. In these cells, in-
sulin stimulates phosphorylation of c-Cbl (Fig. 1 and [16]) but
not in the 3T3-L1 pre-adipocyte. c-Cbl does not associate
directly with the insulin receptor and the variant SH2 domain
of c-Cbl does not bind to phosphorylation sites on the insulin
receptor. This indicates that an accessory adapter or docking
protein is required to facilitate the phosphorylation of c-Cbl
following insulin stimulation. This correlates with the expres-
sion of APS in the di¡erentiated adipocyte. In view of this
correlation, we asked the question whether the expression of
APS is su⁄cient to allow phosphorylation of c-Cbl. As we
have demonstrated (Fig. 3) and as has been previously shown
by Saltiel et al. [16], in CHO.T cells which do not express
APS, insulin does not stimulate c-Cbl tyrosine phosphory-
lation. On the contrary, the overexpression of APS is su⁄cient
to allow insulin-stimulated tyrosine phosphorylation of c-Cbl.
Thus, in contrast to other tyrosine kinase receptors, c-Cbl
phosphorylation in response to insulin can only occur in cells
that co-express insulin receptor and APS indicating the tissue
or cell-type speci¢c nature of insulin-stimulated c-Cbl phos-
phorylation.
What is the physiological role of this insulin-stimulated c-
Cbl phosphorylation? We determined whether the co-expres-
sion of APS was associated with increased receptor ubiquiti-
nation. We found that overexpression of APS enhanced li-
gand-stimulated ubiquitination of the insulin receptor. Thus,
the role of APS in insulin signalling would be to facilitate
coupling of c-Cbl to the insulin receptor in order to facilitate
ubiquitination of the insulin receptor. Therefore target tissues
for insulin such as adipose and skeletal muscle which would
coexpress insulin receptor and APS are likely to have the
unique ability to negatively regulate insulin receptor signalling
by virtue of increased coupling to the c-Cbl, a RING-type E2-
dependent ubiquitin protein ligase [17]. In addition, mono-
ubiquitination may carry a novel internalisation signal that
is appended to activated receptors [27]. We have only ob-
served a single form of the ubiquitinated receptor suggesting
that receptor is mono-ubiquitinated rather than polyubiquiti-
nated. While we have shown that APS is su⁄cient to couple
to c-Cbl, we do not know if it is necessary and whether this is
the only mechanism. The c-Cbl-associated protein CAPS [28]
which is also preferentially expressed in the di¡erentiated adi-
pocyte also couples the insulin receptor to c-Cbl. This insulin
receptor-CAPS-c-Cbl pathway may play a role in enhancing
Fig. 4. Expression of APS enhances ligand-stimulated ubiquitina-
tion. CHO.T cells stably transfected with insulin receptor and/or
APS (CHO.T-APS) were serum-starved, then stimulated with 100
ng/ml insulin for 5 min and lysed. Insulin receptor was then immu-
noprecipitated using anti-insulin receptor monoclonal 83-14. The im-
munoprecipitates were then analysed by immunoblotting using anti-
ubiquitin antibody (top panel). The membrane shown in the top
panel was then stripped and probed for using anti-insulin receptor
peptide polyclonal antibody (bottom panel). Ub, ubiquitin.
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sensitivity to insulin [29], in contrast to the downregulation
that will arise from receptor ubiquitination mediated by APS
and c-Cbl. Thus, these two mechanisms may be mutually ex-
clusive or redundant. Future studies will be required to ad-
dress the relative role of each. It will also be of interest to
determine whether other signalling molecules that interact
with the insulin receptor also undergo increased ubiquitina-
tion as a result of increased coupling to c-Cbl.
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